<DOC>
	<DOC>NCT00367393</DOC>
	<brief_summary>Topical steroid use may lead to skin deterioration and spider veins. This study will examine long-term management of atopic dermatitis (AD) over 12 months with pimecrolimus cream 1% and its effect on skin reconstitution of steroid-damaged skin and disease control.</brief_summary>
	<brief_title>Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>clinically diagnosed AD almost clear to mild AD (local IGA [target lesions face and cubital areas] score of 13) clinically (i.e. to the unaided eye) evident skin atrophy due to longterm topical steroid use Dermatophot Score (DPS composed of skin atrophy and telangiectasia) of 46 on at least two target areas Phototherapy or systemic therapy known or suspected to have an effect on AD within 4 weeks prior to study entry Topical therapy known or suspected to have an effect on AD within 7 days prior to study entry or systemic corticosteroids within 4 weeks prior to study entry Clinical conditions other than AD that according to investigator can interfere with the Dermatophot evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pimecrolimus, skin atrophy, dermoscopy, atopic dermatitis, eczema</keyword>
</DOC>